JIANGSU HORIZON CHAIN SUPERMARKET COMPANY LIMITED 江蘇宏信超市連鎖股份有限公司 （在中華人民共和國註冊成立的股份有限公司） （股份代號：2625） 董事會提名委員會工作細則 第一章 總 則 第一條 為 規 範 江 蘇 宏 信 超 市 連 鎖 股 份 有 限 公 司（以 下 簡 稱「公 司」）董 事 及 高 級 管 理 人 員 的 產 生，優 化 董 事 會 組 成，完 善 公 司 治 理 結 構，根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公 司 法》」）、《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下 簡 稱「《香 港 上 市 規 則》」）、《香 港 上 市 規 則》附 錄C1所 載 的《企 業 管 治 守 則》及《企 業 管 治 報 告》等 相 關 適 用 法 律、行 政 法 規、部 門 規 章、規 範 性 文 件 及 公 司 本 次 境 外 公 開 發 行 股 票 並 上 市 後 適 用 的《江 蘇 宏 信 超 市 連 鎖 股 份 有 限 公 司 章 程》（以 下 簡 稱「《公 司 章 程》」），依 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 JIANGSU HORIZON CHAIN SUPERMARKET COMPANY LIMITED 江蘇宏信超市連鎖股份有限公司 （在中華人民共和國註冊成立的股份有限公司） （股份代號：2625） (1)獨 立 非 執 行 董 事 辭 任； (2)建議委任 獨 立 非 執 行 董 事；及 (3)建議取消監事會與 修訂公司章程及 其附件 獨立非執行董事辭任 林 先 生 及 朱 先 生 各 自 的 辭 任（統 稱「辭任董事」）乃 因 其 計 劃 傾 注 更 多 時 間 於 其 他 事 務。 辭 任 董 事 之 辭 任 須 待 新 任 獨 立 非 執 行 董 事 於 本 公 司 股 東 會（「股東會」）獲 選 後 方 可 生 效。於 此 期 間，辭 任 董 事 將 根 據 相 關 法 律、法 規 ...

Core Viewpoint - The announcements from Pag Biotech-B (02625) reflect a dual approach of "confidence" and "aggression," with cornerstone shareholders extending their lock-up period to express long-term confidence, while simultaneously initiating a placement to raise funds for future growth [1][2]. Group 1: Cornerstone Shareholder Lock-Up - Cornerstone investors have voluntarily extended their lock-up period for the second time, now until April 30, 2024, indicating strong confidence in the company's R&D capabilities and progress towards significant clinical milestones [2]. - This extension signifies that cornerstone investors are not merely financial speculators but are committed industry capital or long-term value investors, willing to sacrifice liquidity to support the company's growth [2]. - The timing of the lock-up extension suggests it may coincide with key R&D milestones or potential international collaborations, reflecting the investors' expectations for positive developments [2]. Group 2: Fundraising Strategy - Pag Biotech plans to raise nearly HKD 300 million through a placement at HKD 58.41 per share, with several well-known institutions acting as joint placement agents [3]. - The funds are earmarked for strategic development rather than immediate financial relief, with a focus on four key areas: digital transformation in R&D, financial health, pipeline sustainability and internationalization, and operational reserves [3][4]. - The first area, digital transformation, will consume HKD 118 million (40% of the total), focusing on building an AI drug discovery platform, a unified database for competitive analysis, and a digital patient platform to enhance drug adherence and collect real-world data [3][4]. Group 3: Financial Health and International Expansion - The second area, financial health, will account for 28% of the funds, aimed at repaying bank loans to reduce interest expenses and optimize financial statements, thereby enhancing the company's resilience during industry downturns [4]. - The third area focuses on ensuring the continuous development of pipeline products PB2301/PB2309 and establishing a subsidiary in Hong Kong to facilitate global expansion, indicating a proactive approach to international collaboration opportunities [4][5]. - The final area, operational reserves, will utilize 10% of the funds to prepare for the upcoming commercialization phase, ensuring the company is well-equipped for future market challenges [5]. Group 4: Overall Strategic Vision - The combination of the fundraising initiative and the cornerstone investors' support creates a synergistic effect, reducing uncertainties associated with the placement and shifting market focus from short-term dilution to long-term value creation [7]. - This strategic approach indicates that the management is not only focused on immediate clinical data but is also considering systematic improvements in overall innovation efficiency and global competitiveness [6].

Core Viewpoint - The announcements from Paig Bio-B (02625) reflect a dual approach of "confidence" and "aggressiveness," with cornerstone shareholders voluntarily locking their shares to express long-term confidence in the company's development while also initiating a placement to raise funds for future expansion [1][2]. Group 1: Cornerstone Shareholder Lock-up - Cornerstone investors have voluntarily extended their share lock-up period to April 30, 2024, demonstrating their strong confidence in the company's R&D capabilities and progress towards significant clinical milestones [2]. - This extension indicates that cornerstone investors are not merely financial speculators but rather long-term value investors, willing to forgo liquidity to support the company's growth [2]. - The timing of the lock-up extension suggests it may coincide with key R&D milestones or potential international collaborations, reflecting the investors' expectations for positive developments [2]. Group 2: Fundraising Strategy - Paig Bio plans to raise nearly HKD 300 million through a share placement at HKD 58.41 per share, with the offering managed by several prominent institutions [3]. - The funds are earmarked for strategic development rather than immediate financial relief, with a focus on four key areas: digital transformation in R&D, financial health, pipeline sustainability, and operational reserves [3][4]. - The first area, digital transformation, will consume HKD 118 million (40% of the total), aimed at enhancing drug discovery through AI and data integration [3][4]. Group 3: Financial Health and Pipeline Development - The second area focuses on financial health, allocating 28% of the funds to repay bank loans, thereby reducing interest expenses and improving cash flow [4]. - The third area emphasizes pipeline sustainability and internationalization, with 12% and 10% of the funds respectively directed towards advancing products PB2301/PB2309 and establishing a subsidiary in Hong Kong for global expansion [4][5]. - The final area, operational reserves, will account for 10% of the funds, preparing the company for the upcoming commercialization phase [5]. Group 4: Market Perception and Future Outlook - The combination of the fundraising initiative and the cornerstone investors' support creates a positive feedback loop, reducing uncertainties associated with the placement and shifting market focus from short-term dilution to long-term value creation [6]. - The management's proactive approach, coupled with the backing from cornerstone investors, positions Paig Bio favorably for future growth and innovation, making it a company to watch in the industry [6].

江苏宏信公布，已于2025年12月2日完成配售约2139.27万股新股，每股H股配售价2.90港元，净筹约 5855万港元。 来源：智通财经网 香港联交所最新资料显示，12月2日，江苏宏信(02625)股东将股票存入胜利证券香港，存仓市值1.01亿 港元，占比9.98%。 ...

江苏宏信公布，已于2025年12月2日完成配售约2139.27万股新股，每股H股配售价2.90港元，净筹约 5855万港元。 香港联交所最新资料显示，12月2日，江苏宏信(02625)股东将股票存入胜利证券香港，存仓市值1.01亿 港元，占比9.98%。 ...

江苏宏信(02625)公布，已于2025年12月2日完成配售约2139.27万股新股，每股H股配售价2.90港元，净 筹约5855万港元。 ...

智通财经APP讯，江苏宏信(02625)公布，已于2025年12月2日完成配售约2139.27万股新股，每股H股配 售价2.90港元，净筹约5855万港元。 ...

格隆汇12月2日丨江苏宏信(02625.HK)公告，董事会欣然宣布，配售协议项下的所有条件已达成，而完 成已于2025年12月2日落实。合共21,392,655股新H股(相当于公司于紧接完成前已发行股本约9.99%以及 公司于紧随完成后经配发及发行配售股份扩大后已发行股本约9.08%)已根据配售协议所载条款及在其条 件规限下按配售价每股H股2.90港元成功配售予不少于六名承配人。 ...

公司名稱： 江蘇宏信超市連鎖股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02625 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股 ...